Samuel Weng

About Samuel Weng

CTO at Nanomics, leading a ~15-member cross-functional team (reagents, MS, automation, data & AI) to build AI- and nanotechnology-enabled proteomics platforms; delivered >30% protein ID increase, improved reproducibility (CV ~20% → ~8%),~85% phosphopeptide enrichment efficiency, user-friendly automation, and the Proteonano™ HT Assay for large-cohort studies with inter-study correction• Proteomics Platform Director at University of Chicago. Oversee and lead all proteomics-related scientific and intellectual development as well as manage platform operation and maintenance• Scientist at AstraZeneca and utilize proteomics techniques to study biomarkers, post-translational modifications, and expression profiling leading to unraveling mechanism of action.• Clinical Cancer Researcher with genomic and proteomics experiences. Familiar with development of various proteomics sample preparation method and statistical analysis of big data. • Bioanalytical Scientist with development of point-of-care diagnostic devices. Familiar with microfluidic technology including biochip design and fabrication. • Research Assistant with development of bioanalyzer and the synthesis of functional magnetic nanoparticles for the concentration of F18. Familiar with product design and simulation, and surface characterization.

Experience

1. Chief Technology Officer

   Nanomics Biotech

   Jan 2026 — Present

   Lead a ~15-member cross-functional team across reagent R&D, mass spectrometry R&D, automation development, data analysis, and AI-driven design• Define and execute technology strategy for nanotechnology-enabled proteomics platforms• Successfully optimized kit performance, achieving-30% increase in protein identifications from identical plasma samples-Improved quantitative reproducibility with CV reduced from ~20% to ~8%• Developed a phosphopeptide enrichment kit with enrichment efficiency up to ~85%• Improved automation platforms to be more user-friendly and scalable for routine and high-throughput use• Led development of the Proteonano™ HT Assay for large-cohort proteomics studies, including inter-study correction• Support business development and marketing by translating technical capabilities into clear product positioning, application narratives, and customer-facing materials

Education

• Simon Fraser University

  Master of Science (M.Sc.), Analytical Chemistry

  2013 — 2016

• The University of British Columbia

  Master of Science (M.Sc.), Pathology and Laboratory Medicine

  2017 — 2019

• Simon Fraser University

  Bachelor of Science (B.Sc.), Chemistry

  2008 — 2012